Blistering skin disorders: An evidence-based update. Conference report

British Journal of Dermatology

Volumn 160, Issue 3, 2009, Pages 502-504

  Alexandroff, A B ^a   Harman, K E ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bullous pemphigoid; Epidermolysis bullosa; Intravenous immunoglobulin; Pemphigus vulgaris; Randomized controlled trial

Indexed keywords

AMITRIPTYLINE; AZATHIOPRINE; BETAMETHASONE VALERATE; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PLACEBO; PREDNISOLONE; RITUXIMAB; TETRACYCLINE;

BULLOUS PEMPHIGOID; CAREGIVER; CHRONIC PAIN; CLINICAL TRIAL; CONFERENCE PAPER; DRUG POTENCY; ECZEMA; EPIDERMOLYSIS BULLOSA; EVIDENCE BASED PRACTICE; HAIR DISEASE; HUMAN; INCIDENCE; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; PSORIASIS; SKIN CANCER; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

AUTOIMMUNE DISEASES; EPIDERMOLYSIS BULLOSA ACQUISITA; EVIDENCE-BASED MEDICINE; HUMANS; PEMPHIGOID, BULLOUS; PEMPHIGUS; SKIN DISEASES, VESICULOBULLOUS;

EID: 60449112472     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08857.x     Document Type: Conference Paper

References (26)

1. Tabolli S, Mozzetta A, Antinone V et al. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire. Br J Dermatol 2008 158 : 1029 34.
2. Gudi VS, White MI, Cruickshank N et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005 153 : 424 7.
3. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003 149 : 926 37.
4. Wojnarowska F, Kirtschig G, Highet AS et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002 147 : 214 21.
5. Marquina M, Espana A, Fernandez-Galar M et al. The role of nitric oxide synthases in pemphigus vulgaris in a mouse model. Br J Dermatol 2008 159 : 68 76.
6. Mentink LF, de Jong MC, Kloosterhuis GJ et al. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. Br J Dermatol 2007 156 : 635 41.
7. Nakashima H, Fujimoto M, Asashima N et al. Serum chemokine profile in patients with bullous pemphigoid. Br J Dermatol 2007 156 : 454 9.
8. Capon F, Bharkhada J, Cochrane NE et al. Evidence of an association between desmoglein 3 haplotypes and pemphigus vulgaris. Br J Dermatol 2006 154 : 67 71.
9. Asashima N, Fujimoto M, Watanabe R et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006 155 : 330 6.
10. Chang YT, Liu HN, Yu CW et al. Cytokine gene polymorphisms in bullous pemphigoid in a Chinese population. Br J Dermatol 2006 154 : 79 84.
11. Shimanovich I, Nitschke M, Rose C et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008 158 : 382 8.
12. Goh MS, McCormack C, Dinh HV et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007 156 : 990 6.
13. Schmidt E, Seitz CS, Benoit S et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007 156 : 352 6.
14. Schmidt E, Herzog S, Brocker EB et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005 153 : 449 51.
15. Cozzani E, Dal Bello MG, Mastrogiacomo A et al. Antidesmoplakin antibodies in pemphigus vulgaris. Br J Dermatol 2006 154 : 624 8.
16. Arin MJ, Engert A, Krieg T et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005 153 : 620 5.
17. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005 153 : 448 9.
18. Pardo J, Mercader P, Mahiques L et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005 153 : 222 3.
19. Joly P, Roujeau JC, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002 346 : 321 7.
20. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007 357 : 545 52.
21. Oh SW, Lee JS, Kim MY et al. Recessive dystrophic epidermolysis bullosa associated with dilated cardiomyopathy. Br J Dermatol 2007 157 : 610 12.
22. Freeman EB, Koglmeier J, Martinez AE et al. Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol 2008 158 : 1308 14.
23. Chan SM, Dillon MJ, Duffy PG et al. Nephro-urological complications of epidermolysis bullosa in paediatric patients. Br J Dermatol 2007 156 : 143 7.
24. Fewtrell MS, Allgrove J, Gordon I et al. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 2006 154 : 959 62.
25. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006 12 : 1397 402.
26. Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008 58 : 1043 6.